We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Contact Radiotherapy Offers New Organ-Preserving Approach for Rectal Cancer

By HospiMedica International staff writers
Posted on 12 Oct 2026

Tampere University Hospital, known as Tays, is the first hospital in Finland to introduce contact radiotherapy for rectal cancer using high-dose-rate brachytherapy, or HDR brachytherapy. More...

The approach is linked to organ-preserving treatment strategies being developed by Tampere University and Tays.

HDR brachytherapy delivers radiation directly to the tumor through a device inserted into the rectum. The technique is designed to concentrate a high radiation dose at the tumor surface while limiting exposure to surrounding healthy tissue. The treatment uses an iridium-192 radiation source.

The approach is not suitable for every rectal cancer patient. Eligibility is assessed by a multidisciplinary team that includes colorectal surgeons, oncologists, radiation oncologists, and radiologists. One important group includes frail and older patients for whom major rectal cancer surgery may be especially burdensome or pose excessive risk.

The treatment is part of the NORPPA research program, which is coordinated by Tampere University and Tays. The research network includes hospitals across Finland and Estonia. The NORPPA-2 study is due to begin in 2027 and will examine the effectiveness of HDR brachytherapy as part of an organ-preserving treatment strategy for rectal cancer.

The study will assess whether intensified local radiotherapy can eradicate tumors and how many patients may avoid major surgery. If local radiotherapy proves sufficiently effective, researchers will also investigate whether some patients could be treated without chemotherapy. If the treatment is confirmed as effective and safe, it could expand the group of patients eligible for organ-preserving care instead of surgery.

“Curing cancer is always our primary goal, but we also want to preserve the best possible quality of life. If a tumor can be completely eradicated without removing the rectum, the patient may—in the best-case scenario—avoid both major surgery and a stoma,” said professor Toni Seppälä from Tampere University and Tays.

“The goal is not to treat the cancer less intensively, but more precisely. We want to identify a treatment that is sufficiently effective for each patient while avoiding treatments and side effects that would yield no additional benefit,” added Seppälä.

Related Links
Tampere University


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Annotation platform for pixel-level labeling of free-text findings in 3D chest CT. (Baharoon M, Luo L, Moritz M, et al. ReXGroundingCT: A 3D chest CT dataset for segmentation of findings from free-text reports. NEJM AI. 2026;3(7). doi:10.1056/AIdbp2501220.)

Public Chest CT Dataset Supports Explainable AI in Diagnostic Radiology

Chest computed tomography scans generate complex three-dimensional images that can be difficult for artificial intelligence systems to explain clearly. Clinicians need to verify AI findings before using... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.